RxDoctor Payments Data

Faiza Qureshi, PA

Physician Assistant · Ridgefield Park, NJNPI 1437586484

Payments from drug & device makers

$660in general payments, 2019–2025

Across 29 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$140
  • Biohaven Pharmaceuticals, Inc.$134
  • GSK$91
  • AbbVie$81
  • Amgen$62
  • Exact Sciences$56
  • plus $96 from 6 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 65th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$29,091
Medicare patients
139
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$111,418
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$34,450
JardianceEmpagliflozin24$21,639
JanuviaSitagliptin Phosphate14$21,035
FarxigaDapagliflozin Propanediol11$11,016
EliquisApixaban12$10,101
Spiriva HandihalerTiotropium Bromide12$6,257
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,581
Rosuvastatin Calcium65$1,831
Albuterol Sulfate HfaAlbuterol Sulfate93$1,807
Atorvastatin Calcium172$1,373
Oxybutynin Chloride ErOxybutynin Chloride22$1,201
Diclofenac Sodium30$1,075
Levothyroxine Sodium116$1,021
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide32$980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$111,41890 claims
GSKTrelegy Ellipta$91$34,45052 claims
AbbVieSynthroid$81$73814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Ridgefield Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →